Record Revenue With Organ Care Still Doing the Work
TransMedics' PR Newswire release put total revenue at $203.0 million for the quarter ended September 30, 2026, up 41% from $143.8 million a year earlier. Organic revenue growth, which excludes PAD Aviation charter services, was 35%. Product revenue was $113.4 million, up 29%. Service revenue was $89.6 million, up 60%, or 43% on an organic basis after stripping $9.4 million of PAD Aviation charter services. Gross margin was 58.5%, versus 58.8% a year earlier. Net income was $17.1 million, or $0.46 per diluted share. Adjusted net income was $18.9 million, or $0.51 per diluted share. Cash was $493.0 million at quarter-end.
Investing.com put Street consensus near $0.30 of EPS and about $177.5 million of revenue, so both headline lines cleared by a wide margin. MarketBeat listed consensus near $0.30 EPS and $178.1 million of revenue. CEO Waleed Hassanein called it the strongest quarter in company history on record revenue and record case volume, even with typical third-quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.
Guidance That Cleared Consensus, Plus Near-Term Catalysts
Full-year 2026 revenue guidance moved to $764 million to $774 million, inclusive of about $14 million from PAD Aviation, or $750 million to $760 million excluding PAD. Investing.com put Street full-year revenue consensus near $741.8 million, so the new band sits above that estimate. Operating highlights in the release included completion of enrollment in ENHANCE Heart Part A, FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung, a first European transplant-logistics tender win in Italy, and the appointment of Fernando Araujo as CFO.
A medtech name that clears the quarter, lifts the year, and still has a stack of clinical and geographic catalysts ahead of it is the classic setup that can gap higher even when the broader tape is selling risk. The release also flagged that PAD Aviation is a new consolidation slice, so traders reading sequential growth need the organic breakout to see how much of the step-up came from organ-care volume versus the aviation add-on.
Twelve to Fourteen Percent Against a Sixteen-to-Eighteen-Percent Band
OptionSlam tracked a roughly 15.81% implied move on the November 6 weekly straddle and about 18.07% on the November 20 monthly into the report. Stocknear showed a pre-report expected move of about ±$12.04, or 17.5%, into the November 6 expiry, with a range near $56.94 to $81.02 centered on the $68.98 close. TipRanks / The Fly had options implying a roughly 16.2% post-earnings move. An after-hours print near $77 to $78.50 is about 12% to 14% above the cash close and still inside those prepaid weekly and monthly bands; the extended-hours high near $83.28 would sit nearer or past Stocknear's weekly upper break-even near $81. Delayed Cboe quotes are a reference for Friday's open rather than fills: spreads can widen after a double-digit gap, after-hours stock prints can fade or extend, and equity options do not trade until 9:30 AM ET.
A Clean Raise That Still Left Room Inside Prepaid Premium
When a name gaps higher by about 12% to 14% after a beat-and-raise and the weekly chain had already collected roughly 16% to 18% of event premium, short straddles and iron condors that sold that move are under less incremental directional pressure than names that cleared their bands by double digits. Long calls that needed a clean break of the weekly upper break-even are only partly paid if the stock opens inside that range and implied volatility resets. Put debit spreads that needed a miss face a tape that bought the raise instead. Our implied volatility guide covers how post-earnings IV usually compresses, and the OCC options disclosure document explains the risks of standardized options, including assignment.
Sources
*By the OptionsPilot Editorial Team. Published November 5, 2026, 10:23 PM PT. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*
